Mesothelioma Staging
Once malignant mesothelioma is found, more tests will be done
to find out if cancer cells have spread to other parts of the body.
This is called mesothelioma staging. A doctor needs to know the
stage of the cancer to plan treatment.
Staging of mesothelioma is based on imaging
studies such as x-rays, CT scans, and MRI scans. The treatment and
outlook for patients with mesothelioma largely depends on the stage
(extent of spread) of their cancer. Since pleural mesothelioma occurs
most frequently and has been studied the most, it is the only mesothelioma
for which a staging classification exists. The following stages
are used for malignant mesothelioma:
Butchart Staging System
The staging system most often used for mesothelioma is the Butchart
system. This system is based mainly on the extent of the primary
tumor mass, and divides mesotheliomas into stages I through IV.
Stage I: Mesothelioma is present within the right or left
pleura, and may also involve the lung, pericardium, or diaphragm
(the muscle separating the chest from the abdomen) on the same side.
Stage II: Mesothelioma invades the chest wall or involves
the esophagus (food passage connecting the throat to the stomach),
heart, or pleura on both sides. The lymph nodes in the chest may
also be involved.
Stage III: Mesothelioma has penetrated through the diaphragm
into the peritoneum (lining of the abdominal cavity). Lymph nodes
beyond those in the chest may also be involved.
Stage IV: There is evidence of distant metastases (spreading
of cancerous cells via the bloodstream to other organs).
TNM Staging System
Another staging system has recently been developed by the American
Joint Committee on Cancer (AJCC).
This is a TNM system, similar to staging systems used for most other
cancers. T stands for tumor (its size and how far it has spread
to nearby organs), N stands for spread to lymph nodes and M is for
metastasis (spread to distant organs). In TNM staging, information
about the tumor, lymph nodes, and metastasis is combined in a process
called stage grouping to assign a stage described by Roman numerals
from I to IV. Minor differences exist between the AJCC TNM staging
system and the Butchart staging system.
Stage I: Mesothelioma involves the right or left pleura.
It may also have spread into the lung, pericardium, or diaphragm
on the same side. It has not yet spread to the lymph nodes.
Stage II: Mesothelioma has spread from the pleura on one
side to the nearby peribronchial and/or hilar lymph nodes next to
the lung on the same side. It may also have spread into the lung,
pericardium, or diaphragm on the same side.
Stage III: Mesothelioma has spread into the chest wall muscle,
ribs, heart, esophagus, or other organs in the chest on the same
side as the primary tumor, with or without spread to subcarinal
and/or mediastinal lymph nodes on the same side as the main tumor.
Subcarinal nodes are located at the point where the windpipe branches
to the left and right lungs. Mediastinal lymph nodes are located
in the space behind the chest bone in front of the heart. Mesotheliomas
with the same extent of local spread as in Stage II that have also
spread to subcarinal and/or mediastinal lymph nodes on the same
side are also included in Stage III.
Stage IV: Mesothelioma has spread into the lymph nodes in
the chest on the side opposite that of the primary tumor, or directly
extends to the pleura or lung on the opposite side, or directly
extends into the peritoneum, or directly extends into organs in
the abdominal cavity or neck. Any mesothelioma with evidence of
distant metastases (spreading to other organs via the bloodstream)
or spread to organs beyond the chest or abdomen is included in this
stage.
Although the recently developed TNM classification is the most detailed
and precise, the original Butchart staging system is still used
most often to describe the spread of pleural mesotheliomas. Understanding
these staging systems for mesothelioma is important both for estimating
and better understanding prognosis, and also for assessing therapeutic
options.
|